Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Published byLynne Gibson Modified over 8 years ago

Similar presentations

Presentation on theme: "Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy."— Presentation transcript:

1 Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy by Jennifer A. Woyach, Kelly Smucker, Lisa L. Smith, Arletta Lozanski, Yiming Zhong, Amy S. Ruppert, David Lucas, Katie Williams, Weiqiang Zhao, Laura Rassenti, Emanuela Ghia, Thomas J. Kipps, Rose Mantel, Jeffrey Jones, Joseph Flynn, Kami Maddocks, Susan O’Brien, Richard R. Furman, Danelle F. James, Fong Clow, Gerard Lozanski, Amy J. Johnson, and John C. Byrd Blood Volume 123(12):1810-1817 March 20, 2014 ©2014 by American Society of Hematology

2 Protein and gene expression of BCR signaling components in persistent lymphocytes compared with baseline. Jennifer A. Woyach et al. Blood 2014;123:1810-1817 ©2014 by American Society of Hematology

3 Nuclear and cytoplasmic localization of BTK, ERK, and AKT in persistent lymphocytes following ibrutinib therapy and ability of persistent lymphocytes to stimulate. Jennifer A. Woyach et al. Blood 2014;123:1810-1817 ©2014 by American Society of Hematology

4 Real-time PCR of BCR pathway–associated genes in persistent lymphocytes. Jennifer A. Woyach et al. Blood 2014;123:1810-1817 ©2014 by American Society of Hematology

5 Persistent lymphocytes are not addicted to a single signaling pathway. Jennifer A. Woyach et al. Blood 2014;123:1810-1817 ©2014 by American Society of Hematology

6 PFS of patients with persistent lymphocytosis is not inferior to those achieving complete or PR by 12 months. Jennifer A. Woyach et al. Blood 2014;123:1810-1817 ©2014 by American Society of Hematology

Download ppt "Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy."

Similar presentations

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
Wilson WH et al. Proc ASH 2012;Abstract 686.

Wilson WH et al. Proc ASH 2012;Abstract 686.
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):3102-3111.

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,

Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,
Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations by Susan Price, Pamela A. Shaw, Amy Seitz, Gyan Joshi, Joie.

Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations by Susan Price, Pamela A. Shaw, Amy Seitz, Gyan Joshi, Joie.
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma by Thomas E. Witzig,

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma by Thomas E. Witzig,
Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B- cell lymphomas by Lingchen Fu, Yen-Chiu Lin-Lee,

Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B- cell lymphomas by Lingchen Fu, Yen-Chiu Lin-Lee,
Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells by Jonathan M. Irish,
The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.
High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia by Marco Herling, Kaushali.

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia by Marco Herling, Kaushali.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,

A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL by Jennifer A. Woyach,
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.
Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia by Chun-Lin Chen, Qing Liu, Ching-Hon Pui,

Higher Frequency of Glutathione S-Transferase Deletions in Black Children With Acute Lymphoblastic Leukemia by Chun-Lin Chen, Qing Liu, Ching-Hon Pui,
Immunosurveillance of Alglucerase Enzyme Therapy for Gaucher Patients: Induction of Humoral Tolerance in Seroconverted Patients After Repeat Administration.

Immunosurveillance of Alglucerase Enzyme Therapy for Gaucher Patients: Induction of Humoral Tolerance in Seroconverted Patients After Repeat Administration.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia by John C. Byrd, Guido Marcucci,

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia by John C. Byrd, Guido Marcucci,
How I treat elderly patients with myeloma

How I treat elderly patients with myeloma
Validation of the Nordic Scoring System for Erythropoietic Stimulating Agents in MDS Using IWG 2006 Erythroid Response Criteria by Jennifer Jayakar, Richard.

Validation of the Nordic Scoring System for Erythropoietic Stimulating Agents in MDS Using IWG 2006 Erythroid Response Criteria by Jennifer Jayakar, Richard.

Similar presentations

Ads by Google